KATY

Personalised medicine has transformed how doctors diagnose patients and treat diseases. Researchers and clinicians are increasingly customising treatments to fit patients’ needs. In cancer care, targeted therapies have been developed as advanced therapeutic options for anti-tumour treatments. The EU-funded KATY project has set out to build a precise personalised medicine system empowered by Artificial Intelligence (AI). The novel AI tool aims to predict the response of kidney cancer to targeted therapies and identify the molecular evidence to support these predictions. Most importantly, the KATY system will offer human interpretable knowledge that clinicians and clinical researchers can trust, adequately evaluate and effectively use in their everyday working routine. Using KATY’s AI-based models in cancer care will boost the use of tailored, targeted treatments.